Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
Chart
The Company has 5 products in clinical trials:
- Safinamide , a unique molecule with a novel dual mechanism of action for the treatment of early and mid-to-late stage Parkinson’s disease
- Ralfinamide, an innovative treatment for neuropathic low back pain with potential in inflammatory pain
- HF 0220 a naturally occurring human steroid for the treatment of Alzheimer's disease and Rheumatoid Arthritis
- HF 0420 a low molecular weight oligosaccharide for the prevention of anti-cancer therapy induced neuropathy
- HF 0299 a naturally occurring human steroid for the treatment of neuropathic pain.